Clinical trials: Obesity, Overweight
Overweight, Obesity
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo).
- Trial name
- OASIS 5 (NCT07770841)
- Testing
- Semaglutide
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Novo Nordisk A/S
Overweight, Healthy Participants
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults.
- Conditions
- Overweight, Healthy Participants, Obesity
- Trial name
- NCT07793019
- Testing
- Orforglipron, IBI3042
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy
Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women
This study will assess if itraconazole will affect the blood levels of Duavee when they are given together. This study will also assess if a subject's body size affects the blood levels of Duavee.
- Trial name
- CE/BZA (NCT02100553)
- Testing
- CE/BZA, Itraconazole
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight, Obesity
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity.
- Trial name
- NCT07557953
- Testing
- Cagrilintide
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Obesity, Muscle Loss
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass.
- Trial name
- PROACT (NCT07101939)
- Testing
- (S)-pindolol benzoate, Semaglutide
- Where
- 7 sites in Serbia
- Volunteers
- 120 people
- Sponsor
- Actimed Therapeutics Ltd
Overweight, Obesity
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities.
- Trial name
- NCT06023095
- Testing
- LY3502970
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Obesity
Clinical Observation of Implementing the MedGem Into a Medical Specialty Practice
Due to common CVD diseases associated from obesity, medical providers are in a position to provide assistance. However, less than 10% of all patients receive any weight loss advice from physicians.
- Trial name
- NCT00489502
- Testing
- Brief Counseling, REE Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Microlife
Healthy, Overweight
Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)
The purpose of this study is to evaluate whether 30 mg of pioglitazone administered once daily for up to 28 days to healthy overweight and obese subjects will lead to a significant change in insulin sensitivity, measured in the…
- Conditions
- Healthy, Overweight, Obesity
- Trial name
- NCT01115712
- Testing
- Comparator: Pioglitazone, Comparator: Hyperinsulinemic Euglycemic Clamp
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide.
- Trial name
- NCT06388187
- Testing
- Cagrilintide, Semaglutide
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Obesity
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and…
- Trial name
- RAMBO (NCT07010432)
- Testing
- Cagrilintide, Semaglutide
- Where
- Denmark
- Volunteers
- 144 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased…
- Trial name
- SURMOUNT-1 (NCT07481747)
- Testing
- Tirzepatide, Reduced-calorie diet
- Where
- China
- Volunteers
- 2,539 people
- Sponsor
- Hudson Biotech
Obesity
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects…
- Trial name
- NCT05064735
- Testing
- semaglutide 2.4 mg
- Where
- 122 sites in United States, Canada and 9 more
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid…
- Trial name
- NCT07247084
- Testing
- Tirzepatide, Standard of Care
- Where
- 30 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Eli Lilly and Company
Obesity
Phase 1 Study of NGM313 in Healthy Adult Participants
The purpose of this study is to determine the safety and tolerability of NGM313, both single dose and multiple doses, in normal healthy overweight and obese adult participants.
- Trial name
- NCT02708576
- Testing
- NGM313
- Where
- Australia
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
Obesity, Dyslipidemia
Obese Patients With Untreated Dyslipidemias
To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia
- Trial name
- RIO-Lipids (NCT00029835)
- Testing
- Rimonabant (SR141716)
- Where
- 35 sites in United States, Australia and 6 more
- Volunteers
- 1,033 people
- Sponsor
- Sanofi
Obesity
Safety and Efficacy of APD356 in the Treatment of Obesity
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.
- Trial name
- NCT00116740
- Testing
- APD356
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
POMC Deficiency Obesity, PCSK1 Deficiency Obesity
An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes
This is an observational study. There are no protocol-defined visits, although patients are expected to have routine office visits approximately every 6 months.
- Conditions
- POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
- Trial name
- NHS (NCT03621007)
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 8 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Diabetes
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
- Trial name
- NCT04973111
- Testing
- CT-868 as SC Injection, Active Comparator as SC Injection
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Overweight and Obesity
A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of DA-302168S tablets in overweight and obese adults.
- Trial name
- DA168 (NCT06953063)
- Testing
- DA-302168S
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Overweight or Obesity
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with…
- Trial name
- NCT07170319
- Testing
- IBI3032
- Where
- China
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.